APD  Vol.4 No.4 , November 2015
Safety and Efficacy of a Transdermal Rotigotine for the Treatment of Fatigue and Quality of Life in Patients with Parkinson’s Disease
ABSTRACT
Aim: To evaluate safety and efficacy of a transdermal rotigotine for the treatment of fatigue and quality of life (QOL) in patients with Parkinson’s disease (PD). This was a multi-sites open-label study of 58 PD patients (male 26, female 32) who met a Japanese PD diagnosis criterion. They received a transdermal rotigotine 4.5 mg/day for 8 weeks. We added a rotigotine on the previous anti-Parkinson’s drugs. Clinical signs were evaluated by Hoehn-Yahr (H-Y) stage, unified Parkinson’s disease rating scale (UPDRS), fatigue severity scale (FSS), and Euro quality of life (QOL). The scores of UPDRS improved from 35.2 ± 8.0 (mean ± SD) to 31.8 ± 8.3 (P = 0.14). There was no significant improvement or worsening of the H-Y stages. The scores of FSS improved from 57.3 ± 12.7 (mean ± SD) to 50.1 ± 11.8 (P = 0.061). The scores of QOL improved from 38.1 ± 11.1 to 48.3 ± 10.0 (P = 0.068). Our data demonstrate that, in a small sample size, administration of a transdermal rotigotine was associated with few side effects and was modestly effective for the treatment of fatigue and QOL in patients with PD.

Cite this paper
Abe, K. , Fujita, M. and Yoshikawa, H. (2015) Safety and Efficacy of a Transdermal Rotigotine for the Treatment of Fatigue and Quality of Life in Patients with Parkinson’s Disease. Advances in Parkinson's Disease, 4, 79-83. doi: 10.4236/apd.2015.44009.
References
[1]   Parkinson, J. (2002) An Essay on the Shaking Palsy. Journal of Neuropsychiatry and Clinical Neurosciences, 14, 223- 236. http://dx.doi.org/10.1176/jnp.14.2.223

[2]   Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonism: Onset, Progression and Mortality. Neurology, 17, 427-442. http://dx.doi.org/10.1212/WNL.17.5.427

[3]   Jankovic, J. (2008) Parkinson’s Disease: Clinical Features and Diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79, 368-376. http://dx.doi.org/10.1136/jnnp.2007.131045

[4]   Chaudhuri, K.R. and Schapira, A.H. (2009) Non-Motor Symptoms of Parkinson’s Disease: Dopaminergic Pathophysiology and Treatment. Lancet Neurology, 8, 464-474.
http://dx.doi.org/10.1016/S1474-4422(09)70068-7

[5]   Antonini, A., Barone, P., Marconi, R., Morgante, L., Zappulla, S., Pontieri, F.E., et al. (2012) The Progression of Non- Motor Symptoms in Parkinson’s Disease and Their Contribution to Motor Disability and Quality of Life. Journal of Neurology, 259, 2621-2631. http://dx.doi.org/10.1007/s00415-012-6557-8

[6]   Rey, C.K., Angero, S., Kapil, S.D., Anthony, S.H.V., Richard, B., Angelo, A., Fabrizio, S., Per, O., Kristy, B., Yoshio, T., Kazuo, A., Alexandra, R., Carmen, R.-B. and Pablo, M.-M. (2015) The Burden of Non Motor Symptoms in Parkinson’s Disease Using a Self-Completed Non-Motor Questionnaire: A Simple Grading System. Parkinsonism & Related Disorders, 21, 287-291.
http://dx.doi.org/10.1016/j.parkreldis.2014.12.031

[7]   Barone, P. (2010) Neurotransmission in Parkinson’s Disease: Beyond Dopamine. European Journal of Neurology, 17, 364-376. http://dx.doi.org/10.1111/j.1468-1331.2009.02900.x

[8]   Naidu, Y. and Chaudhuri, K.R. (2007) Transdermal Rotigotine: A New Non-Ergot Dopamine Agonist for the Treatment of Parkinson’s Disease. Expert Opinion on Drug Delivery, 4, 111-118.
http://dx.doi.org/10.1517/17425247.4.2.111

[9]   Elshoff, J.P., Braun, M., Andreas, J.O., Middle, M. and Cawello, W. (2012) Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies. Clinical Therapeutics, 34, 966-978.
http://dx.doi.org/10.1016/j.clinthera.2012.02.008

[10]   Baldwin, C.M. and Keating, G.M. (2007) Rotigotine Transdermal Patch. CNS Drugs, 21, 1039-1066.
http://dx.doi.org/10.2165/00023210-200721120-00007

[11]   Trenkwalder, C., Kies, B., Rudzinska, M., Fine, J., Nikl, J., Honczarenko, K., et al. (2011) Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson’s Disease: A Double-Blind, Randomized, Placebo-Controlled Study (RECOVER). Movement Disorders, 26, 90-99.
http://dx.doi.org/10.1002/mds.23441

[12]   Mizuno, Y. (1997) Concept and Diagnostic Criteria of Parkinson’s Disease and Parkinsonism. Nihon Rinsho. Japanese Journal of Clinical Medicine, 55, 16-20.

[13]   Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): Status and Recommendations. Movement Disorders, 18, 738-750. http://dx.doi.org/10.1002/mds.10473

[14]   Abe, K., Takanashi, M. and Yanagihara, T. (2000) Fatigue in Patients with Parkinson’s Disease. Behavioral Neurology, 12, 103-106. http://dx.doi.org/10.1155/2000/580683

[15]   Martinez-Martin, P., Schapira, B.R. and The EuroQol Group (1996) EuroQol: The Current State of Play. Health Policy, 37, 53-72. http://dx.doi.org/10.1016/0168-8510(96)00822-6

[16]   Coelho, M. and Ferreira, J.J. (2012) Late-Stage Parkinson Disease. Nature Reviews Neurology, 8, 435-442. http://dx.doi.org/10.1038/nrneurol.2012.126

[17]   Chaudhuri, K.R., Martinez-Martin, P., Brown, R.G., Sethi, K., Stocchi, F., Odin, P., Ondo, W., Abe, K., MacPhee, G., MacMahon, D., Barone, P., Rabey, M., Bonnuccelli, U., Forbes, A., Breen, K., Tluk, S., Naidu, Y., Olanow, C.W., Thomas, S., Rye, D., Bowron, A., Williams, A.J. and Schapira, A.H.V. (2007) The Metric Properties of a Novel Non- Motor Symptoms Scale for Parkinson’s Disease: Results from an International Pilot Study. Movement Disorders, 22, 1901-1911. http://dx.doi.org/10.1002/mds.21596

[18]   Martinez-Martin, P., Rodriguez-Blazquez, C., Bkurtis, M.M., Chaudhuri, K.R. and The NMSS Validation Group (2011) The Impact of Non Motor Symptoms on Health-Related Quality of Life of Patients with Parkinson’s Disease. Movement Disorders, 26, 399-406. http://dx.doi.org/10.1002/mds.23462

[19]   Martinez-Martin, P., Rodriguez-Blazquez, C., Abe, K., Bhattacharyya, K.B., Bloem, B.R., Carod-Artal, J., Dill, B., Esselink, R., Falup-Pecurariu, C., Gallardo, M., Mir, P., Naidu, Y., Nicoletti, A., Sethi, K., Tsuboi, Y., van Hilten, J.J., Visser, M., Zappia, M. and Chaudhuri, K.R. (2009) International Validation of the Non-Motor Symptoms Scale: Comparison with the Pilot Study. Neurology, 73, 1584-1591.
http://dx.doi.org/10.1212/WNL.0b013e3181c0d416

[20]   Stocchi, F., Abbruzzese, G., Ceravolo, R., Cortelli, P., D’Amelio, M., De Pandis, M.F., Fabbrini, G., Pacchetti, C., Pezzoli, G., Tessitore, A., Canesi, M., Iannacone, C., Zappia, M. and FORTE Study Group (2014) Prevalence of Fatigue in Parkinson’s Disease and Its Clinical Correlates. Neurology, 83, 215-220.
http://dx.doi.org/10.1212/WNL.0000000000000587

[21]   Barone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T.P., Bottacchi, E., Cannas, A., Ceravolo, G., Ceravolo, R., Cicarelli, G., Gaglio, R.M., Giglia, R.M., Iemolo, F., Manfredi, M., Meco, G., Nicoletti, A., Pederzoli, M., Petrone, A., Pisani, A., Pontieri, F.E., Quatrale, R., Ramat, S., Scala, R., Volpe, G., Zappulla, S., Bentivoglio, A.R., Stocchi, F., Trianni, G., Dotto, P.D. and PRIAMO Study Group (2009) The PRIAMO Study: A Multicenter Assessment of Nonmotor Symptoms and Their Impact on Quality of Life in Parkinson’s Disease. Movement Disorders, 24, 1641-1649.
http://dx.doi.org/10.1002/mds.22643

 
 
Top